Skip to main content

Pharma News

 

Clinical courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Researchers have identified a molecular marker that identifies proliferating cells in normal breast tissue and can predict a woman's risk of developing breast cancer, the leading cause of death in women with cancer worldwide.

  • Andhra Pradesh is all set to introduce rotavirus vaccine to combat diarrhoeal deaths among children, an official said on Thursday.The state has received 460,000 doses of rotavac, the country's first indigenous rotavirus vaccine.

    (adsbygoogle = window.adsbygoogle || []).push({});
  • Countries with higher male smoking rates such as India and Bangladesh can push up asthma and wheezing cases as a result of more exposure to second-hand smoke.This is what Jayadeep Patra, an epidemiologist at the Centre for Global Health Research at St. Michael's Hospital in Toronto, says.

  • Today on 4th April 2016, first report of The National Institutional Ranking Framework (NIRF) announcing national level rankings in categories of Engineering, Management, Pharmacy and Universities were announced.  NIRF is an initiative by the Ministry of Human Resouce Development and launched by Honourable Minister of Human Resource Development on 29th September, 2015. It aims to rank insititutes on objective parameters on national scale which can help in promoting healthy cometition among the institues and can provide better information to various stakeholders of the society.

  •  Celltrion, a global biopharmaceutical company,  announced that the U.S. Food and Drug Administration (FDA) has approved INFLECTRA™ (biosimilar infliximab, sold in Europe as Remsima®) for all indications of the reference product, Janssen Biotech Inc.'s Remicade® (infliximab). INFLECTRA is the first biosimilar monoclonal antibody (mAb) medication to receive approval in the U.S., and is indicated for the treatment of patients with a number of serious autoimmune diseases, including Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.

  • Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has entered a worldwide collaboration and license agreement with Tesaro, Inc., for exclusive rights to the investigational compound niraparib in prostate cancer. Niraparib is an orally administered poly polymerase (PARP) inhibitor, currently in late-stage development for patients with metastatic breast cancer and ovarian cancer.

  • Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) approved a new four-dose, multi-dose vial (MDV) presentation of Prevenar 13®* (pneumococcal polysaccharide conjugate vaccine [13 – valent, adsorbed]). This new MDV presentation was developed to help maximize efficiency for health care workers by helping to significantly reduce storage requirements and shipping costs in communities with health systems that are still developing.

Subscribe to Pharma News